

EXHIBIT B

Drug Databases (<https://www.fda.gov/Drugs/InformationOnDrugs/>)

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

[Home \(index.cfm?resetfields=1\)](#) | [Back to Product Details](#)

Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
- As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N.214324

Product 001

TREPROSTINIL (TYVASO DPI) POWDER 0.016MG/INH

Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
001	9593066	12/15/2028	DS				06/17/2022
001	10130685	08/23/2025		DP			06/17/2022
001	10421729	04/01/2035		DP			06/17/2022
001	10716793	05/14/2027			<u>U-1849</u>	Y	06/17/2022
001	10772883	06/11/2030		DP			06/17/2022
001	11357782	05/14/2027			<u>U-1849</u>		04/24/2025
001	11723887	12/15/2028	DS				08/15/2023
001	11826327	02/03/2042			<u>U-3749</u>		11/28/2023

Exclusivity Data

Product No	Exclusivity Code	Exclusivity Expiration
001	<u>NP</u>	05/23/2025

[View a list of all patent use codes \(results_patent.cfm\)](#)

[View a list of all exclusivity codes \(results_exclusivity.cfm\)](#)